Analysts at Citigroup assumed coverage on shares of Candel Therapeutics (NASDAQ:CADL - Get Free Report) in a report issued on Thursday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $25.00 price target on the stock. Citigroup's target price indicates a potential upside of 138.78% from the company's current price.
Several other research firms have also recently weighed in on CADL. Bank of America assumed coverage on shares of Candel Therapeutics in a research note on Friday, February 7th. They issued a "buy" rating and a $15.00 target price for the company. Canaccord Genuity Group started coverage on shares of Candel Therapeutics in a research report on Wednesday. They set a "buy" rating and a $20.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $19.00 price objective (up from $11.00) on shares of Candel Therapeutics in a research report on Wednesday, December 18th.
Check Out Our Latest Research Report on Candel Therapeutics
Shares of CADL opened at $10.47 on Thursday. The stock has a market capitalization of $340.07 million, a P/E ratio of -6.05 and a beta of -1.25. Candel Therapeutics has a twelve month low of $1.34 and a twelve month high of $14.60. The company has a 50 day moving average of $8.06 and a 200-day moving average of $6.54.
In related news, Director Paul B. Manning purchased 1,250,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was acquired at an average price of $6.00 per share, with a total value of $7,500,000.00. Following the completion of the purchase, the director now directly owns 1,303,752 shares in the company, valued at $7,822,512. This trade represents a 2,325.49 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Seshu Tyagarajan sold 14,322 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the completion of the transaction, the chief technology officer now directly owns 96,790 shares of the company's stock, valued at approximately $698,823.80. This trade represents a 12.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 75,856 shares of company stock valued at $470,044. 41.60% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of CADL. Baker BROS. Advisors LP acquired a new position in Candel Therapeutics in the fourth quarter valued at about $25,884,000. Acorn Capital Advisors LLC acquired a new position in Candel Therapeutics in the fourth quarter valued at about $16,836,000. Braidwell LP acquired a new position in Candel Therapeutics in the fourth quarter valued at about $13,888,000. Portolan Capital Management LLC acquired a new position in Candel Therapeutics in the fourth quarter valued at about $6,543,000. Finally, Halter Ferguson Financial Inc. raised its stake in Candel Therapeutics by 123.7% during the fourth quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company's stock worth $5,914,000 after acquiring an additional 376,795 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company's stock.
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.